Harnessing (and Securing) Meaningful Data



John Halamka talks about the future of health data.

May 18, 2010 | “There isn’t going to be some massive database in the basement of the White House run by Sarah Palin,” promised John Halamka, the CIO of Harvard Medical School, in his keynote at the Bio-IT World Expo. But there will be a “federated mechanism that enables us to send data from place to place for a whole variety of purposes for care and research.”

Halamka serves as the Chair of the US Healthcare Information Technology Standards Panel. Of the $30 billion allotted to health care IT in the Obama Administration’s stimulus package, most of it will be distributed to hospitals and clinics after they’ve put health care IT infrastructure in place and are using it wisely. The remaining $2 billion is being distributed by the Office of the National Coordinator for health care IT advances.

“Here’s the strategy,” Halamka said. “Give $2 billion in grants to accelerate the industry. Give the industry a set of standards that are unambiguous for everything from medications, to labs, to quality measurements, to both clinical care and population health… Declare how hospitals and doctors have to use this wisely, and then certify products as being good enough to have the features and functions and capabilities to make this whole thing work.”

In the next five years as these standards are put into place, doctors and hospitals will be required to collect “meaningful” data and protect that data. “This is not using a word processor to record data!” Halamka clarified. “This is actually using codified mechanisms so that if you capture medications, problems, allergies, labs, etc. You could use them to inform drug discovery.”

Meaningful data include requiring all orders to be electronic; recording medication and allergy lists for all patients; and recording and updating demographics and vital signs in a timely manner—all using consistent and controlled vocabularies.

There are rules that still need to be clarified, Halamka says, but gathering meaningful data will begin to enable smarter health care. Offices and hospitals will be able to mine their data and send targeted wellness reminders for preventative care. Patients will have access to a continuity of care document, delivered electronically, explaining treatment history, prescriptions, and diagnoses.

But with this wealth of data—and wealth of possibilities—comes a huge security responsibility. Halamka stressed that laptops and thumb drives must be encrypted. Patient privacy must be protected.

“I spend about $1 million a year just protecting the Beth Israel Deaconess [hospital] records against the nefarious internet. We’re attacked every seven seconds, 24 hours a day, seven days a week,” Halamka said. “Half of the attacks come from Eastern Europe; half of the attacks come from Eastern Cambridge. Every September, 1200 new hackers arrive – they’re called freshmen!”

Emerging Data

Although about 20% of clinics and hospitals currently have electronic health records, all should by 2015. Public health applications are already beginning to emerge. Health data gathered can be aggregated regionally to look at public health trends or build doctor report cards. The SureScripts (representing pharmacies) and RxHub (representing payors) database includes de-identified drug information on 160 million people that can be used to check for drug interactions.

In another example, the Social Security Administration used to spend $500 million a year getting paper records. After moving to electronic records two years ago, a disability claim that took months to adjudicate can be handled in 48 hours.

There are even opportunities to gather rich patient data in the home. Halamka is testing a bathroom scale that calculates his lean body mass and body mass index and transmits the data via XML in real time to Google Health and Microsoft Health. But although an avid blogger and registered technophile, he said he declined the Twitter reporting feature.


This article also appeared in the May-June 2010 issue of Bio-IT World Magazine. Subscriptions are free for qualifying individuals. Apply today.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .